Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide

BackgroundNesiritide is approved for the treatment of decompensated heart failure. Because nesiritide may exacerbate renal dysfunction, it has been claimed that there may be a link between worsening renal function caused by nesiritide and increased mortality.AimsWe analyzed our inpatient experience with nesiritide to determine if changes in renal function were associated with worsened mortality.Methods and resultsA retrospective study of 167 patients [65% male, median age 70 years, left ventricular ejection fraction (LVEF) 30%, glomerular filtration rate (GFR) 36 mL/min/1.73 m2, serum creatinine (sCr)1.8 mg/dL] treated with standard dose nesiritide was undertaken for the period September 2001–March 2005. Mortality was 12.5% at 1 month and 51% at 24 months (median follow-up was 5.4 months [interquartile ranges (IQR) 1.3, 18.6]. Higher mortality was associated with lower pre-infusion GFR (hazard ratio for a 10 mL/min/1.72 m2 decrease = 1.22, p = 0.004). Pre-to-post nesiritide changes in GFR (median 0.0, IQR—5.8, 8.4; p = 0.51) and creatinine (median 0.0, IQR − 0.3, 0.3; p = 0.91), however, were not significant and not detected to be associated with worsened mortality by Cox proportional hazards (p = 0.46 and p = 0.40, respectively).ConclusionsWhile we found that nesiritide infusion in decompensated heart failure patients worsened renal function (decrease in GFR) in 29% of patients, changes in renal function could not be related to an incremental worsening of mortality. Our findings do not support an association of worsening renal function and worsening mortality after nesiritide.